Blue Matter Blog

12 Pitfalls in Europe: Pitfall #9 – Missing a Promotable Label
March 28, 2022

At some point in its development, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive for various reasons, including its large population, high per-capita spend on healthcare, and vast market potential. But successfully entering Europe is a complex undertaking, and biopharma companies need to know …

12 Pitfalls in Europe: Pitfall #8 – Failing to Realize that Early Access Programs (EAPs) Can Boost…or Bite
March 27, 2022

At some point in its development, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive for various reasons, including its large population, high per-capita spend on healthcare, and vast market potential. But successfully entering Europe is a complex undertaking, and biopharma companies need to know …